NONALCOHOLIC FATTY LIVER DISEASE - SOME ASPECTS OF PREVENTION

Аннотация

Nowadays, NAFLD is considered one of the leading causes of chronic liver diseases globally. This is probably because a patient with NAFLD usually had more severe diseases - diabetes mellitus type 2 (DM-2), metabolic syndrome, etc. On the one hand, after it was established that insulin resistance underlies these metabolic diseases and, on the other hand, that compensation for these conditions does not eliminate NAFLD, and the presence of NAFLD worsens the course of the underlying disease, interest in its study increased significantly. The development of NAFLD is increasingly associated with the hypothesis of multifactorial parallel effects, or "multiple parallel hits" ("multiple parallel hits"). According to this hypothesis, the pathogenesis of NAFLD appears to be a model that generalizes the interaction of such complex factors as BP, FWS formation, adipocytokines and the gut microbiota, which is involved in the regulation of metabolism, systemic inflammation, BP, highlighting the role of the immune system in metabolic inflammation in NAFLD. Given the disease's pathogenesis, hypolipidemic agents from the group of fibrates can be effective in patients with NAFLD. NAFLD treatment's general goals should be to improve patient's quality of life, reduce hepatic and cardiovascular morbidity and mortality, prevent the development and progression of concomitant pathology of the digestive organs. Modern therapeutic tactics presuppose lifestyle modification and medication.